Apam-Garduño David, Cazarín-Barrientos Jorge, Hernández-Martínez Nancy Leticia, Reyna-Fabián Miriam Erandi, Magaña Mario, Alcántara-Ortigoza Miguel Angel, González-Del Angel Ariadna, Rivera-Vega María Refugio
Servicio de Genética, Hospital General de México, Mexico City, Mexico.
Servicio de Dermatología, Hospital General de México, Mexico City, Mexico.
J Cutan Pathol. 2023 Jun;50(6):481-486. doi: 10.1111/cup.14340. Epub 2022 Nov 23.
Folliculocystic and collagen hamartoma (FCCH) is a rare entity with only 18 reported cases worldwide. Of them, most are found in patients diagnosed with tuberous sclerosis complex (TSC). FCCH has distinctive histopathologic features, including collagen deposition in the dermis, perifollicular fibrosis, and comedones with keratin-containing cysts lined by infundibular epithelium. We report three patients with a definitive TSC clinical diagnosis in whom clinical, histopathologic, and molecular features were studied to establish if there exists a genotype-phenotype correlation. The molecular results showed different heterozygous pathogenic variants (PV) in TSC2 in each patient: NM_000548.4:c.5024C>T, NG_005895.1:c.1599+1G>T, and NM_000548.4:c.2297_2298dup, to our knowledge; the latter PV has not been reported in public databases. The same PVs were identified as heterozygous in the tumor tissue samples, none of which yielded evidence of a TSC2 second hit. Because all FCCH patients with available molecular diagnosis carry a pathogenic genotype in TSC1 or TSC2, we suggest that FCCH should be considered as a new and uncommon diagnostic manifestation in the TSC consensus international diagnostic criteria. The early recognition of FCCH by clinicians could prompt the identification of new TSC cases. Interestingly, our molecular findings suggest that one of the patients described herein is a probable case of somatic mosaicism.
毛囊囊肿性和胶原性错构瘤(FCCH)是一种罕见病症,全球仅报告了18例。其中,大多数病例见于诊断为结节性硬化症复合体(TSC)的患者。FCCH具有独特的组织病理学特征,包括真皮中的胶原沉积、毛囊周围纤维化以及含有由漏斗状上皮衬里的含角蛋白囊肿的粉刺。我们报告了3例临床确诊为TSC的患者,对其临床、组织病理学和分子特征进行了研究,以确定是否存在基因型-表型相关性。分子检测结果显示,每位患者的TSC2基因均存在不同的杂合致病性变异(PV):据我们所知,分别为NM_000548.4:c.5024C>T、NG_005895.1:c.1599+1G>T和NM_000548.4:c.2297_2298dup;后者的PV在公共数据库中尚未见报道。在肿瘤组织样本中也鉴定出相同的杂合PV,均未发现TSC2基因二次打击的证据。由于所有已进行分子诊断的FCCH患者在TSC1或TSC2中均携带致病性基因型,我们建议在TSC国际诊断共识标准中,应将FCCH视为一种新的、不常见的诊断表现形式。临床医生对FCCH的早期识别可能会促使发现新的TSC病例。有趣的是,我们的分子检测结果表明,本文所述的一名患者可能是体细胞镶嵌现象的病例。